Tuvirumab (OST 577; SDZ-OST 577) is a humanIgG1subclass monoclonal antibody directed againstHBVsurface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research^[1][2].

Tuvirumab (OST 577; SDZ-OST 577; 5 mg/kg; iv; single dose) followed by intravenous wild-type HBV, the MS-2 strain, directs against the a determinant of HBV surface antigen delayed but does not prevent experimental infection of HBV and hepatitis in the chimpanzee^[1].
Tuvirumab (5 mg/kg; iv) has a half-life of 16.7 days in the chimpanzee^[1].

138660-97-6

妥韦单抗

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.